by Barry101 | Oct 30, 2023 | Press Release
OCALA, Fla., Oct. 30, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including...
by Barry101 | Oct 17, 2023 | Uncategorized
OCALA, Fla., Oct. 17, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced it has entered into an agreement with Azenova, LLC (“Azenova”), a professional business development (BD) consulting firm, to support efforts to...
by Barry101 | Oct 17, 2023 | Press Release
OCALA, Fla., Oct. 17, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced it has entered into an agreement with Azenova, LLC (“Azenova”), a professional business development (BD) consulting firm, to support efforts to...
by Barry101 | Sep 22, 2023 | Press Release
OCALA, Fla., Sept. 22, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced Chris McAleer, Ph.D., Scientific Officer of AIM will present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer...
by Barry101 | Sep 11, 2023 | Press Release
Complete topline results confirm treatment was well tolerated, with promising clinical activity of pathologic complete response (pCR) + microinvasive residual disease (ypTmic) at 66%, comparable to pembrolizumab/neoadjuvant chemotherapy (NAC) Planned Phase 2 study in...
